Novo Nordisk said on Monday it would lower the U.S. price of its injectable Wegovy obesity drug and pledged to go "all in" on ...

The Danish drugmaker said it's cutting the price of Wegovy and Ozempic from $499 to $349 per month for some customers who buy ...

Novo Holdings, which controls obesity drugmaker Novo Nordisk , will sell 154.5 million shares, or 7.8% of its stake, in ...

Facing increased competition in the weight loss market and intense pressure from President Donald Trump, Novo Nordisk ...

The Danish anti-obesity drugmaker slashed prices for its Wegovy and Ozempic treatments. Shares fell more than 1%. ↘️ [XPeng ...

Novo Nordisk has more than enough of its Wegovy weight-loss pills to support an aggressive product launch, CEO Mike Doustdar ...

Novo Nordisk plans “all in” launch of Wegovy pill in the US market and will cut price of the drug's injectable option in the ...

Novo Nordisk offers limited-time $199 pricing on Wegovy and Ozempic, lowers self-pay costs, and prepares for a stronger ...

Novo Nordisk cuts obesity drug prices to compete with Eli Lilly, offering new patient deals and nationwide access.

Novo Nordisk is chopping prices again for its popular obesity treatment Wegovy, but doctors say the expense will remain ...

New cash-paying patients can now access Wegovy/Ozempic for $199 a month. Here's what that means for Novo Nordisk stock.